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Abstract 
Liver X receptors (LXRs) play an important role in lipid metabolism. Recently, a role for these proteins 
was identified in suppressing the inflammatory response. However it is not known whether the natural 
ligands of LXRs, e.g. 22(R)-hydroxycholesterol (22R-HC), can suppress the inflammatory response after 
the onset of inflammation. We demonstrate here that treatment of lipopolysaccharide-activated RAW 
264.7 macrophages with 22R-HC markedly suppressed nitric oxide (NO) production and inducible NO 
synthase (iNOS) and cyclooxygenase-2 (COX-2) mRNA expression. Additionally, 22R-HC did not affect 
the DNA binding activity of NF-κB, AP-1 and C/EBP(s), important transcriptional factors for iNOS and 
COX-2 genes expression. Furthermore iNOS and COX-2 mRNA suppression by 22R-HC was diminished 
by cellular treatment with cycloheximide. These results suggest that 22R-HC suppresses the expression of 
iNOS and COX-2 genes through de novo protein synthesis of an unidentified protein in LPS-activated 
macrophages.  
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Introduction 
Liver X receptors (LXRs), a family of nuclear receptors, heterodimerize with retinoid X receptor (RXR) 
and bind specific elements (LXREs) characterized by direct repeats spaced by four nucleotides [1-4].The 
LXR signaling pathway is thought to play an important role in lipid metabolism [5-12]. Recent data 
suggests that the LXR pathway antagonizes the NF-κB signaling pathway and inihibits the expression of 
inflammatory genes downstream of NF-κB [13,14]. 
22(R)-hydroxycholesterol (22R-HC) is an intermediate produced during the biosynthesis of 
pregnenolone from cholesterol in cytochrome p450 C27 side chain cleavave [15]. As 22R-HC binds 
directly to LXRs and specifically activates LXR transcriptional activity [5, 6, 16]. In addition, when 
macrophages derived from wild-type mice were pretreated with 22R-HC, LPS-induced iNOS expression 
was inhibited. However, when macrophages derived from LXRαβ-/- mice were pretreated with 22R-HC, 
LPS-induced iNOS expression was not inhibited [13]. These results suggest that 22R-HC is one of natural 
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ligands for LXRs and might have an anti-inflammatory property through LXR pathway in macrophages. 
In most clinical situation, inflammations likely exists at the time of therapy, and the possible clinical 
application of anti-inflammatory is limited if compounds cannot suppress pre-existing inflammation. It 
is not known whether 22R-HC can suppress the inflammatory response, even if the treatment is initiated 
shortly after the onset of inflammation.  
Expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) is induced 
shortly after the onset of inflammation and these protein play critical roles in the tissue response to 
injury and infection [18-20]. Although the activity of iNOS and COX-2 is essential during states of 
infection and wound healing, aberrant or excessive expression of either iNOS or COX-2 has been 
implicated in the pathogenesis of many disease processes, such as septic shock, rheumatoid arthritis and 
atherosclerosis [21-23]. 
In this study, we examined the effect of 22R-HC treatment on iNOS and COX-2 mRNA expression 
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after the onset of inflammation using RAW264.7 macrophages that are fully activated by LPS. In this 
model, 22R-HC repressed NO production and iNOS mRNA expression even when macrophages were 
fully activated by LPS. In addition, we found that 22R-HC also repressed COX-2 mRNA expression 
and the inhibitory effect of 22R-HC on iNOS and COX-2 mRNA expression required de novo protein 
synthesis. 
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Materials and Methods 
 Reagent. 22(R)-hydroxycholesterol, dexamethasone, RU486, cycloheximide and lipopolysaccharide 
(LPS) from Salmonella typhimurium were purchased from Sigma (St. Louis, MO). [α-32P]dCTP 
(~220TBq/mmol) was purchased from Amersham Biosciences Corp. (Piscataway, NJ). 
Cell Culture. RAW264.7 cells, which are murine monocyte/macrophage cell line, were obtained from 
the American Type Culture Collection (Manassas, VA). RAW264.7 cells were cultured in DMEM 
medium containing 10% fetal bovine serum (FBS; Biological Industries, Ashrat, Israel) plus penicillin 
(100 units/ml) and streptomycin (100 μg/ml). DMEM medium and Penicillin-Streptomycin were 
purchased from Gibco/Invitrogen corp. (Carlsbad, CA). 
Nitrite Assays. At the indicated time points, the culture medium was collected for nitrite measurement, 
which was used as a measure of NO production. Culture medium (100 μl) was incubated with same 
volume of Griess reagent (0.1% N-1-(napthyl)ethylenediamine dihydrochloride, 1% sulfanilamide and 
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2.5% H3PO4), and the absorbance was measured at 550 nm [24]. The concentration of nitrite was 
calculated with sodium nitrite as a standard. 
RNA analysis. Total RNA was extracted from RAW264.7 cells using Trizol reagent (Invitrogen, Tokyo, 
Japan). For Northern blots, total RNA (20 μg/lane) was separated on 1% formaldehyde agarose gels, 
transferred to Hybond XL nylon membranes (Amersham Biosciences). After UV cross-linking, the 
membranes were prehybridized, hybridized with a specific cDNA probe for iNOS, COX-2 or β-actin as 
below, washed according to the manufacture’s instructions of Hybond HL and exposed to Hyperfirm MP 
(Amersham Biosciences). The levels of iNOS mRNA, COX-2 mRNA and β-actin mRNA were calculated 
on the basis of signals as measured by an image analyzer, BAS2000 (Fuji Photo Film. Co., Tokyo, Japan). 
The cDNAs for murine iNOS and murine β-actin mRNA were obtained from total RNA of mouse 
peritoneal macrophages by reverse transcriptase-polymerase chain reaction (RT-PCR) as described 
previously [25], using the following primers: iNOS Fwd, 5’-cacatctggcagaatgagaagctg-3’; iNOS Rev, 
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5’-acacttcgcacaaagcagggcac-3’; β-actin Fwd, 5’-gagagggaaatcgtgcgtga-3’; β-actin Rev, 
5’-acacttcgcacaaagcagggcac-3’. The cDNA fragment of murine iNOS or murine β-actin was subcloned in 
the pCRII-TOPO vector (Invitrogen) and their nucleotide sequences were confirmed by LI-COR DNA 
sequencer 4200 (LI-COR, Lincoln, NE) (iNOS: GenBank accession number U43428, β-actin: GenBank 
accession number M12481). For iNOS and β-actin cDNA probes, a 1.4-kb insert of iNOS in the 
pCRII-TOPO vector was digested with EcoRI, and a 0.45-kb insert of β-actin in the pCRII-TOPO vector 
was digested with EcoRI. For COX-2 cDNA probes, a 1.6-kb insert of COX-2 in the pBluescript KS 
vector was digested with HindIII (GenBank accession number M88242). The digested cDNA fragments 
of iNOS, COX-2 or β-actin were separated on 1x TAE agarose gels, purified by QIAquick gel extraction 
kit (Qiagen, Tokyo, Japan) and labeled with [α-32P]dCTP using Rediprime II random primer labeling 
system (Amersham Biosciences). 
Preparation of nuclear protein extracts and electrophoretic mobility shift assays (EMSAs). 
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RAW264.7 cells were plated at a density of 2 X 106 cells in 10 cm diameter dishes, activated, harvested, 
and resuspended in hypotonic buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM 
EGTA, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail (Complete EDTA 
free; Roche Diagnostics, Tokyo, Japan)) for 15 min on ice, then vortexed for 10 s with 0.6% Nonidet P-40. 
Nuclei were separated from cytosol by centrifugation at 12,000 X g for 60 s and were resuspended in 
buffer C (10 mM HEPES, 25% glycerol, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM 
phenylmethylsulfonyl fluoride, protease inhibitor cocktail) and briefly sonicated on ice. Nuclear extracts 
were obtained by centrifugation at 12,000 X g for 20 min. Protein concentration was measured by the 
method of Bradford [26] by using the protein dye reagent (Bio-Rad Laboratories, Tokyo, Japan). For 
binding reactions, nuclear extracts (5 μg of protein) were incubated in 25 μl of total reaction volume 
containing 20 mM HEPES, 50 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 5% glycerol, 200 μg/ml bovine 
serum albumin, and 1.25 μg of poly(dI-dC) for 15 min at 4 oC. The 32P-labeled oligonucleotide probe was 
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added to the reaction mixture and incubated for 20 min at room temperature. The reaction products were 
analyzed by electrophoresis in 8% polyacrylamide gel with 0.25 X TBE buffer. The gel was dried and 
analyzed by autoradiography. The 32P-labeled oligonucleotide probe was prepared as described below. 
Double-stranded oligonucleotides were prepared by annealing the complementary single strands. 
Double-stranded oligonucleotides were radiolabeled with Klenow fragment of DNA polymerase I (Roche 
Diagnostics) and [α-32P]dCTP (Amersham Biosciences) in a fill-in reaction for 5’-protruding ends. 
EMSAs were performed with 32P-labelled double-stranded oligonucleotide probes representing the 
consensus sequences of the following transcriptional factors: NF-κB 
(5’-gatcAGTTGAGGGGACTTTCCCAGGC-3’), AP-1 (5’-gatcCGCTTGATGTCAGCCGGAA-3’), 
C/EBP (5’-gatcTGCAGATTGCGCAATCTGCA-3’). 
Statistical analysis. Results were expressed as mean ± S.E.M. When indicated, statistical significance 
was calculated by analyses of variance supported by the Scheffe multiple comparisons test. Differences 
 11 
were considered significant at p<0.05. 
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Results 
22R-HC inhibits NO production when administered after LPS activation of RAW264.7 
macrophages. 
We examined whether NO production in LPS-activated RAW264.7 macrophages was repressed 
following treatment with 22R-HC. 22R-HC was added to the cells 18 h before (-18 h), simultaneously (0 
h) or 4 h after LPS activation (4 h), and cells were activated for 24 h with LPS in the absence or presence 
of 22R-HC. 22R-HC inhibited NO production by LPS-activated RAW264.7 cells under all conditions 
tested (Fig. 1A). Additionally, 22R-HC-mediated inhibition of NO production was dose dependent (Fig. 
1B). 
22R-HC suppresses iNOS mRNA expression in LPS-activated RAW264.7 cells. 
22R-HC-mediated inhibition of NO production could arise from either a failure to upregulate iNOS 
expression or an inhibition of iNOS activity. To test the first hypothesis, we examined the effect of 
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22R-HC treatment on iNOS mRNA expression in LPS-activated macrophages by Northern blotting. LPS 
activation alone induced marked iNOS expression, and the addition of 22R-HC reduced the levels of 
iNOS mRNA expression (Fig 2A). Consistent with the inhibitory effect of 22R-HC on NO production, 
this effect was also dose dependent (Fig. 2A). Inhibition of iNOS expression did not become apparent 
until 4 h, but the difference in mRNA levels were marked by 8 h (Fig. 2B). The repression rate was 64% 
at 12 h (Fig. 2C), but this inhibition disappeared at 24 h (data not shown). 
22R-HC has no inhibitory effect on DNA binding activity of NF-κB, AP-1 and C/EBP(s). 
NF-κB is an important transcription factor regulating LPS-induced iNOS expression [27]. Therefore we 
examined whether 22R-HC inhibited the DNA binding activity of NF-κB, using an electrophoretic 
mobility shift assays. 22R-HC had no inhibitory effect on NF-κB DNA-binding activity at all time points 
(Fig. 3A). 22R-HC also had no effect on DNA binding activity of AP-1 and C/EBP(s), additional 
transcription factors capable of binding the iNOS promoter and facilitating iNOS genes expression [28] 
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(Fig. 3B and 3C). 
22R-HC inhibition of iNOS mRNA expression requires de novo protein synthesis. 
Because 22R-HC is thought to be a natural ligand for LXRs, we hypothesized that 22R-HC may induce 
de novo protein(s) synthesis through LXR pathway and the induced protein(s) may suppress the 
expression of iNOS gene. Using a protein-synthesis inhibitor cycloheximide, we examined by Northern 
blotting whether the inhibition of iNOS expression required de novo protein synthesis. By cellular 
treatment with cycloheximide, the suppression of iNOS mRNA expression by 22R-HC was diminished 
(Fig. 4A and 4B). Thus, de novo protein synthesis is reuquired for the inhibition of iNOS expression by 
22R-HC.  
22R-HC-mediated inhibition of NO production is independent of the glucocorticoid receptor 
pathway. 
Glucocorticoid treatment is also known to inhibit NO production, and the glucocorticoid receptor 
 15 
antagonist RU486 diminishes this effect (28). Since 22R-HC is a biosynthetic precursor of glucocorticoid, 
22R-HC might be converted to glucocorticoid in RAW264.7 cells. To rule out this possibility, we 
examined the effect of 22R-HC treatment on NO production in LPS-activated macrophages in the 
presence of the glucocorticoid receptor antagonist RU486. RU486 abolished the inhibitory effect of 
dexamethasone on NO production, but RU-486 did not block the inhibitory effect of 22R-HC on NO 
production (Fig. 5). Thus, 22R-HC inhibits NO production in LPS-activated RAW264.7 cells 
independently of glucocorticoid receptor pathway. 
22R-HC inhibits COX-2 mRNA expression in LPS-activated RAW264.7 cells. 
We examined the effect of 22R-HC on COX-2 mRNA expression in LPS-activated RAW264.7 cells in a 
manner similar to that used for iNOS. Like iNOS expression, COX-2 mRNA expression was also 
suppressed by 22R-HC, but, dose response and time course of the repression differed. 22R-HC inhibited 
COX-2 mRNA expression at 3 μM (Fig. 6A), and COX-2 mRNA expression was suppressed 4 h after 
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22R-HC administration. This effect was maximal at 8 h (Fig. 6B and 6C). Additionally, COX-2 mRNA 
expression was also diminished by cellular treatment with cycloheximide even in the presence of 22R-HC 
(Fig 4A and 4C).  
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Discussion 
In the present study, we clearly demonstrated that 22R-HC inhibits NO production and iNOS and 
COX-2 mRNA expression in LPS-activated RAW264.7 macrophages. These results suggest that 22R-HC 
can negatively regulate excess NO and inflammatory prostaglandin production during an inflammatory 
response, even after the onset of inflammation. This is especially important for the clinical application of 
anti-inflammatory therapies because, in most cases, treatment is not initiated until after the initiation of 
the inflammatory response. Sepsis is systemic inflammatory response to infection associated with 
coagulopathy, multi organ failure, and death [23, 30]. Bacterial toxins induce host cells to release NO, 
prostaglandins and cytokines, and all of these compounds are likely related to the pathogenesis of sepsis. 
Although medical treatment is typically initiated after the onset of sepsis, few compounds substantially 
improve motality after sepsis has begun. However, lysophosphatidylcholine and nicotine are effective 
even when treatment occur after the induction of peritonitis [31, 32]. Based on the current study, 22R-HC 
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may also be effective post hoc treatment for sepsis, and this should be investigated using models of sepsis 
such as cecal ligation and puncture. 
Joseph et al. showed that a synthetic LXR agonist repressed the transcriptional activity of NF-κB, but 
not that of AP-1 in the presence of LXR, using a luciferase reporter assay [13]. It has been shown that the 
LXR agonist inhibits NF-κB-induced MMP-9 gene expression through LXR activation without affecting 
NF-κB DNA binding activity [17]. We also observed that 22R-HC did not affect the DNA binding 
activities of NF-κB, AP-1 and C/EBP. These results suggest that LXR agonists did not affect the DNA 
binding activity of NF-κB but lowered mRNA levels of two genes regulated by this transcription factor. 
Castrillo et al. provided evidence that Toll-like receptor (TLR) and LXR signaling pathway may compete 
for limiting amounts of transcriptional co-activators such as p300 and CBP [33]. It is possible to speculate 
that suppression of iNOS and COX-2 mRNA expression by 22R-HC may result from the competition of 
p300 and CBP between TLR and LXR signal pathway. However, since only this molecular mechanism 
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can not simply explain why the treatment of cycloheximide diminishes the suppression of iNOS and 
COX-2 mRNA expression, other mechanisms may exist. 
22R-HC had no suppressive effect on iNOS and COX-2 mRNA expression in cycloheximide-treated 
cells. These results suggest that suppression of iNOS and COX-2 mRNA expression by 22R-HC requires 
de novo protein synthesis. It is thought that there are at least two hypotheses about how 22R-HC represses 
these genes expression thorough de novo protein synthesis. As the first hypothesis, 22R-HC might induce 
unidentified protein(s) that modulate the stability of iNOS and COX-2 mRNA. It has been reported that 
dexamethasone also inhibits iNOS mRNA expression in LPS-activated RAW264.7 cells [29]. Although 
the molecular mechanism remains uncertain, dexamethasone appears to reduce iNOS mRNA stability and 
suppress the accumulation of iNOS mRNA. 22R-HC may also reduce iNOS and COX-2 mRNA stability. 
As we do not determine whether 22R-HC reduces iNOS and COX-2 mRNA stability, it has two 
possibilities, transcriptional or posttranscriptional regulation. More investigations will be needed. As the 
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second hypothesis, 22R-HC might induce unidentified protein(s) that repress transcriptional activity of 
NF-κB. This repressor(s) might be LXR-induced gene product. Although LXR pathway suppress TLR 3/4 
signal pathway, the mechanism remains uncertain. If we could identify this repressor(s), we would be able 
to understand the crosstalk between LXR and TLR signal pathway. 
Recently, roles for nuclear receptor corepressor (N-CoR) and the closely related silencing mediator for 
retinoic acid and thyroid hormone receptor (SMRT) as the overall regulators of NF-κB transcription 
activity have been identified [34, 35]. N-CoR- and SMRT-containing complexes is known to interact with 
Sin 3 and recruit the histone deacetylases that lead to hypoacetylation of histones and transrepression of 
target transcription factors. It is possible that these complexes may be related to 22R-HC suppression of 
iNOS and COX-2 mRNA expression. , and this possibility needs to be investigated. 
In summary, our results demonstrate that 22R-HC inhibits NO production and iNOS and COX-2 mRNA 
expression, even when administered after macrophage activation. This inhibitory effect requires de novo 
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protein synthesis through the glucocorticoid receptor independent pathway. 
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Figure Legends 
Fig. 1 
22R-HC inhibits NO production in LPS-activated RAW 264.7 macrophages. 
(A) RAW264.7 cells were activated for 24 h with LPS (100 ng/ml) in absence or presence of 22R-HC 
(12 μM). 22R-HC was added to the cells 18 h before (-18 h), simultaneously (0 h) or 4 h after LPS 
activation (4 h). (B) RAW264.7 cells were treated with the indicated concentration of 22R-HC (0, 3, 6, 12 
μM) for 24 h after being incubated with LPS (100 ng/ml) for 4 h. NO was detected as nitrite in the culture 
medium. Results were expressed as mean ± S.E.M. (n=9). *P<0.05 significantly lower than the samples 
with LPS activation only. 
Fig. 2 
22R-HC inhibits iNOS mRNA expression in LPS-activated RAW264.7 macrophages. 
(A) RAW264.7 cells were activated with LPS (100 ng/ml) for 4 h and treated with the indicated 
 24 
concentration of 22R-HC (0, 3, 6 or 12 μM) for 12 h. Total RNA was isolated, and total RNA (20 μg per 
lane) was analyzed for iNOS mRNA expression levels by Northern blotting. The relative amount of iNOS 
mRNA was measured by an image analyzer BAS2000 after normalization with that of β-actin. Similar 
results were obtained in two additional experiments. ND; not detect. NC; negative control. (B) 
RAW264.7 cells were activated with LPS (100 ng/ml) for 4 h and treated with or without 22R-HC (12 
μM) for the indicated time. Total RNA was isolated, and total RNA (20 μg per lane) was analyzed for 
iNOS mRNA expression levels by Northern blotting. The relative amount of iNOS mRNA was measured 
by an image analyzer BAS2000 after normalization with that of β-actin. Similar results were obtained in 
two additional experiments. ND; not detect. NC; negative control. (C) Percent (%) Repression represents 
the ratio of iNOS mRNA level of RAW264.7 macrophages treated with 22R-HC to that of RAW264.7 
macrophages treated without 22R-HC at each time point. 
Fig. 3 
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22R-HC has no effect on DNA-binding activity of NF-κB or AP-1 or C/EBP(s) in LPS-activated 
RAW264.7 macrophages. 
RAW 264.7 cells were activated with LPS (100 ng/ml) for 4 h and then treated with 22R-HC (12μM) for 
the indicated time. Nuclear extracts were incubated with 32P-labeled oligonucleotides containing 
consensus binding site for NF-κB or AP-1 or C/EBP and analyzed by electrophoretic mobility shift assay 
as described in materials and methods. The gels are representatives of three separate experiments with 
similar result. (A) NF-κB, (B) AP-1, (C) C/EBP(s).  NS; non specific band. 
Fig. 4 
22R-HC inhibition of iNOS mRNA expression requires de novo protein synthesis. 
RAW264.7 cells were activated with LPS (100 ng/ml) for 4 h and treated with or without 22R-HC (12 
μM) or cycloheximide (3.6 μM) for the indicated time. Total RNA was isolated, and total RNA (20 μg per 
lane) was analyzed for iNOS mRNA expression levels by Northern blotting. The relative amount of iNOS 
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mRNA was measured by an image analyzer BAS2000 after normalization with that of β-actin. Similar 
results were obtained in two additional experiments. ND; not detect. NC; negative control. 
Fig. 5 
22R-HC mediated inhibition of NO production is independent of the glucocorticoid receptor pathway. 
RAW264.7 cells were activated with LPS (100ng/ml) and treated with or without RU486 (1μM) for 
30min prior to the addition of 22R-HC (12μM) or dexamethasone (1μM) and the cells were further 
incubated for an additional 24 h. NO was detected as nitrite in the culture medium. Results were 
expressed as mean ± S.E.M. (n=6). *P<0.05 significantly lower than the samples with LPS activation only. 
DEX; dexamethasone. 
Fig. 6 
22R-HC inhibits COX-2 mRNA expression in LPS-activated RAW264.7 macrophages. 
RAW264.7 cells were activated with LPS (100 ng/ml) for 4 h and treated with the indicated 
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concentration of 22R-HC (0, 3, 6 or 12 μM) for 12 h. Total RNA was isolated, and total RNA (20 μg per 
lane) was analyzed for COX-2 mRNA expression levels by Northern blotting. The relative amount of 
COX-2 mRNA was measured by an image analyzer BAS2000 after normalization with that of β-actin. 
Similar results were obtained in two additional experiments. ND; not detect. NC; negative control. (B) 
RAW264.7 cells were activated with LPS (100 ng/ml) for 4 h and treated with or without 22R-HC (12 
μM) for the indicated time. Total RNA was isolated, and total RNA (20 μg per lane) was analyzed for 
COX-2 mRNA expression levels by Northern blotting. The relative amount of COX-2 mRNA was 
measured by an image analyzer BAS2000 after normalization with that of β-actin. Similar results were 
obtained in two additional experiments. ND; not detect. NC; negative control. (C) Percent (%) Repression 
represents the ratio of iNOS mRNA level of RAW264.7 macrophages treated with 22R-HC to that of 
RAW264.7 macrophages treated without 22R-HC at each time point. 
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